#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	531	11930	16S	1529	1529	99.87	16S.l15.c4.ctg.1	2098	564.5	0	.	n	.	0	A662G	SNP	662	662	A	921	921	G	695	G,A	646,1	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	531	11930	16S	1529	1529	99.87	16S.l15.c4.ctg.1	2098	564.5	0	.	n	.	0	C1450T	SNP	1450	1450	C	1709	1709	T	674	T,C	628,2	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	531	11930	16S	1529	1529	99.87	16S.l15.c4.ctg.1	2098	564.5	1	SNP	n	C1184T	0	.	.	1184	1184	C	1443	1443	C	677	C	647	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	22490	23S	2890	2890	99.93	23S.l15.c30.ctg.1	3447	648.9	0	.	n	.	0	G1337A	SNP	1337	1337	G	1648	1648	A	768	A	737	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	22490	23S	2890	2890	99.93	23S.l15.c30.ctg.1	3447	648.9	0	.	n	.	0	T1971C	SNP	1971	1971	T	2282	2282	C	756	C	717	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	22490	23S	2890	2890	99.93	23S.l15.c30.ctg.1	3447	648.9	1	SNP	n	A2045G	0	.	.	2045	2045	A	2356	2356	A	691	A	659	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	22490	23S	2890	2890	99.93	23S.l15.c30.ctg.1	3447	648.9	1	SNP	n	C2597T	0	.	.	2597	2597	C	2908	2908	C	710	C	674	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	22490	23S	2890	2890	99.93	23S.l15.c30.ctg.1	3447	648.9	0	HET	.	.	.	G262A	.	262	262	G	573	573	G	725	G,A	486,162	.	.
folP.WHO_F_01537c	folP.WHO_F_01537c	1	1	539	1818	folP	852	852	99.88	folP.l15.c4.ctg.1	1516	119.4	0	.	p	.	0	A204V	NONSYN	610	612	GCA	946	948	GTA	175;179;179	G;T;A	164;165;169	.	.
folP.WHO_F_01537c	folP.WHO_F_01537c	1	1	539	1818	folP	852	852	99.88	folP.l15.c4.ctg.1	1516	119.4	1	SNP	p	R228S	0	.	.	682	684	CGC	1018	1020	CGC	195;197;199	C;G;C	184;187;189	folP.WHO_F_01537c:1:1:R228S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	539	5112	gyrA	2751	2751	99.96	gyrA.l6.c4.ctg.1	3431	148.5	0	.	p	.	0	V371I	NONSYN	1111	1113	GTT	1404	1406	ATT	183;182;184	A;T;T	177;177;178	.	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	539	5112	gyrA	2751	2751	99.96	gyrA.l6.c4.ctg.1	3431	148.5	1	SNP	p	S91F	0	.	.	271	273	TCC	564	566	TCC	174;172;171	T;C;C	163;160;165	gyrA.WHO_F_00668c:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	539	5112	gyrA	2751	2751	99.96	gyrA.l6.c4.ctg.1	3431	148.5	1	SNP	p	D95G	0	.	.	283	285	GAC	576	578	GAC	169;170;171	G;A;C	165;163;167	gyrA.WHO_F_00668c:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	539	5112	gyrA	2751	2751	99.96	gyrA.l6.c4.ctg.1	3431	148.5	1	SNP	p	D95N	0	.	.	283	285	GAC	576	578	GAC	169;170;171	G;A;C	165;163;167	gyrA.WHO_F_00668c:1:1:D95N:gyrA.95N:Resistance to fluoroquinolones	.
mtrR.WHO_U_01459	mtrR.WHO_U_01459	1	1	27	1476	mtrR	633	633	100.0	mtrR.l15.c30.ctg.1	1286	113.9	1	SNP	p	G45D	0	.	.	133	135	GGC	477	479	GGC	174;171;169	G;G;C	164;161;158	mtrR.WHO_U_01459:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	531	734	mtrR_promoter	250	250	99.6	mtrR_promoter.l15.c17.ctg.1	1002	73.0	0	.	n	.	0	.206T	INS	206	206	T	612	612	T	161	T	154	.	.
parC.WHO_G_00206c	parC.WHO_G_00206c	1	1	539	5066	parC	2304	2304	99.83	parC.l15.c17.ctg.1	3025	166.6	0	.	p	.	0	G459S	NONSYN	1375	1377	GGT	1654	1656	AGT	202;200;199	A;G;T	194;189;189	.	.
parC.WHO_G_00206c	parC.WHO_G_00206c	1	1	539	5066	parC	2304	2304	99.83	parC.l15.c17.ctg.1	3025	166.6	1	SNP	p	D86N	0	.	.	256	258	GAC	535	537	GAC	210;207;205	G;A;C	199;192;196	parC.WHO_G_00206c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_G_00206c	parC.WHO_G_00206c	1	1	539	5066	parC	2304	2304	99.83	parC.l15.c17.ctg.1	3025	166.6	1	SNP	p	S87R	0	.	.	259	261	AGT	538	540	AGT	206;202;205	A;G;T	196;192;191	parC.WHO_G_00206c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_G_00206c	parC.WHO_G_00206c	1	1	539	5066	parC	2304	2304	99.83	parC.l15.c17.ctg.1	3025	166.6	1	SNP	p	S87W	0	.	.	259	261	AGT	538	540	AGT	206;202;205	A;G;T	196;192;191	parC.WHO_G_00206c:1:1:S87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_G_00206c	parC.WHO_G_00206c	1	1	539	5066	parC	2304	2304	99.83	parC.l15.c17.ctg.1	3025	166.6	1	SNP	p	S87I	0	.	.	259	261	AGT	538	540	AGT	206;202;205	A;G;T	196;192;191	parC.WHO_G_00206c:1:1:S87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_G_00206c	parC.WHO_G_00206c	1	1	539	5066	parC	2304	2304	99.83	parC.l15.c17.ctg.1	3025	166.6	1	SNP	p	S88P	0	.	.	262	264	TCC	541	543	TCC	205;209;203	T;C;C	195;197;197	parC.WHO_G_00206c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	3890	parE	1986	1986	100.0	parE.l15.c4.ctg.1	2541	152.1	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1520	1522	GGC	183;183;181	G;G;C,G	172;174;167,1	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.22.001	penA.22.001	1	1	27	3428	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2339	146.0	1	SNP	p	A311V	0	.	.	931	933	GCA	1214	1216	GCA	180;180;176	G;C;A	169;167;167	penA.22.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.22.001	penA.22.001	1	1	27	3428	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2339	146.0	1	SNP	p	I312M	0	.	.	934	936	ATC	1217	1219	ATC	175;174;174	A;T;C	164;167;167	penA.22.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.22.001	penA.22.001	1	1	27	3428	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2339	146.0	1	SNP	p	V316T	0	.	.	946	948	GTG	1229	1231	GTG	177;177;178	G;T;G	173;168;172	penA.22.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.22.001	penA.22.001	1	1	27	3428	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2339	146.0	1	SNP	p	V316P	0	.	.	946	948	GTG	1229	1231	GTG	177;177;178	G;T;G	173;168;172	penA.22.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.22.001	penA.22.001	1	1	27	3428	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2339	146.0	1	SNP	p	T484S	0	.	.	1450	1452	ACC	1733	1735	ACC	197;197;196	A;C;C	182;189;187	penA.22.001:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.22.001	penA.22.001	1	1	27	3428	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2339	146.0	1	SNP	p	A502P	0	.	.	1504	1506	GCG	1787	1789	GCG	179;178;181	G;C;G	160;142;157	penA.22.001:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.22.001	penA.22.001	1	1	27	3428	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2339	146.0	1	SNP	p	A502V	0	.	.	1504	1506	GCG	1787	1789	GCG	179;178;181	G;C;G	160;142;157	penA.22.001:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.22.001	penA.22.001	1	1	27	3428	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2339	146.0	1	SNP	p	G543S	0	.	.	1627	1629	GGT	1910	1912	GGT	148;148;149	G;G;T	144;143;144	penA.22.001:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.22.001	penA.22.001	1	1	27	3428	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2339	146.0	1	SNP	p	G546S	0	.	.	1636	1638	GGC	1919	1921	GGC	149;145;144	G,T;G;C	142,1;140;137	penA.22.001:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.22.001	penA.22.001	1	1	27	3428	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2339	146.0	1	SNP	p	P552S	0	.	.	1654	1656	CCG	1937	1939	CCG	131;131;132	C;C;G	100;113;107	penA.22.001:1:1:P552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_F_00106	ponA.WHO_F_00106	1	1	27	5014	ponA	2397	2397	99.96	ponA.l6.c30.ctg.1	3031	164.4	1	SNP	p	L421P	0	.	.	1261	1263	CTG	1621	1623	CTG	199;200;200	C;T,C;G	183;181,1;184	ponA.WHO_F_00106:1:1:L421P:ponA.421P:High-level chromosomally-mediated penicillin resistance	.
porA.NCCP11945	porA.NCCP11945	1	0	531	2136	porA	1146	1146	99.56	porA.l15.c17.ctg.1	1688	125.3	0	.	p	.	0	S22G	NONSYN	64	66	AGC	372	374	GGC	153;154;156	G;G;C,A	140;140;142,1	.	.
porA.NCCP11945	porA.NCCP11945	1	0	531	2136	porA	1146	1146	99.56	porA.l15.c17.ctg.1	1688	125.3	0	.	p	.	0	M83fs	FSHIFT	247	247	A	554	554	C	155	C	145	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2320	porB1b	1041	1041	96.47	porB1b.l15.c4.ctg.1	1588	145.4	0	.	p	.	0	V75I	NONSYN	223	225	GTT	555	557	ATT	189;191;195	A,G;T;T	177,2;179;182	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2320	porB1b	1041	1041	96.47	porB1b.l15.c4.ctg.1	1588	145.4	0	.	p	.	0	T89S	NONSYN	265	267	ACC	597	599	AGC	213;212;212	A;G,C;C	202;197,2;199	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2320	porB1b	1041	1041	96.47	porB1b.l15.c4.ctg.1	1588	145.4	0	.	p	.	0	V98I	NONSYN	292	294	GTC	624	626	ATC	206;205;203	A,G;T;C	189,1;191;190	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2320	porB1b	1041	1041	96.47	porB1b.l15.c4.ctg.1	1588	145.4	0	.	p	.	0	.	MULTIPLE	358	359	AA	689	690	CG	190;184	C;G,A	181;171,1	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2320	porB1b	1041	1041	96.47	porB1b.l15.c4.ctg.1	1588	145.4	0	.	p	.	0	.	MULTIPLE	361	362	GA	692	694	CAG	186;188;187	C,G;A;G	174,1;174;176	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2320	porB1b	1041	1041	96.47	porB1b.l15.c4.ctg.1	1588	145.4	0	.	p	.	0	N122K	NONSYN	364	366	AAC	696	698	AAA	190;191;192	A;A;A,C	181;184;183,1	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2320	porB1b	1041	1041	96.47	porB1b.l15.c4.ctg.1	1588	145.4	0	.	p	.	0	F131Y	NONSYN	391	393	TTT	723	725	TAT	218;221;222	T;A,T;T	197;200,1;204	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2320	porB1b	1041	1041	96.47	porB1b.l15.c4.ctg.1	1588	145.4	0	.	p	.	0	N134E	NONSYN	400	402	AAT	732	734	GAG	213;213;218	G,A;A;G,T	199,1;199;203,1	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2320	porB1b	1041	1041	96.47	porB1b.l15.c4.ctg.1	1588	145.4	0	.	p	.	0	V135F	NONSYN	403	405	GTG	735	737	TTT	218;219;218	T,G;T;T,G	203,1;206;204,1	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2320	porB1b	1041	1041	96.47	porB1b.l15.c4.ctg.1	1588	145.4	0	.	p	.	0	G140K	NONSYN	418	420	GGA	750	752	AAA	204;210;209	A;A;A	191;196;194	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2320	porB1b	1041	1041	96.47	porB1b.l15.c4.ctg.1	1588	145.4	0	.	p	.	0	K143E	NONSYN	427	429	AAA	759	761	GAA	216;217;218	G;A;A	197;199;199	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2320	porB1b	1041	1041	96.47	porB1b.l15.c4.ctg.1	1588	145.4	0	.	p	.	0	V151A	NONSYN	451	453	GTA	783	785	GCA	221;221;223	G;C;A	207;206;206	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2320	porB1b	1041	1041	96.47	porB1b.l15.c4.ctg.1	1588	145.4	0	.	p	.	0	T213S	NONSYN	637	639	ACA	969	971	TCA	195;196;199	T;C;A	185;189;190	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2320	porB1b	1041	1041	96.47	porB1b.l15.c4.ctg.1	1588	145.4	0	.	p	.	0	G253Q	NONSYN	757	759	GGA	1089	1091	CAA	165;164;163	C;A;A	158;157;158	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2320	porB1b	1041	1041	96.47	porB1b.l15.c4.ctg.1	1588	145.4	0	.	p	.	0	.	INDELS	760	762	ACA	1093	1097	ATCAA	161;161;161;158;158	A;T;C;A;A	156;157;157;154;154	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2320	porB1b	1041	1041	96.47	porB1b.l15.c4.ctg.1	1588	145.4	0	.	p	.	0	.	INDELS	763	764	TG	1100	1102	AGT	156;159;159	A;G;T	153;155;154	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2320	porB1b	1041	1041	96.47	porB1b.l15.c4.ctg.1	1588	145.4	0	.	p	.	0	A257D	NONSYN	769	771	GCT	1107	1109	GAT	164;161;162	G;A;T	159;154;156	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2320	porB1b	1041	1041	96.47	porB1b.l15.c4.ctg.1	1588	145.4	0	.	p	.	0	D292N	NONSYN	874	876	GAT	1212	1214	AAT	181;182;182	A,G;A;T	172,1;177;177	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2320	porB1b	1041	1041	96.47	porB1b.l15.c4.ctg.1	1588	145.4	0	.	p	.	0	D293S	NONSYN	877	879	GAT	1215	1217	AGT	182;181;183	A,G;G,A;T	175,1;176,1;173	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2320	porB1b	1041	1041	96.47	porB1b.l15.c4.ctg.1	1588	145.4	0	.	p	.	0	N295D	NONSYN	883	885	AAC	1221	1223	GAC	184;183;180	G,A;A;C,G	175,1;175;175,1	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2320	porB1b	1041	1041	96.47	porB1b.l15.c4.ctg.1	1588	145.4	0	.	p	.	0	H296Y	NONSYN	886	888	CAC	1224	1226	TAC	179;180;179	T,C;A;C	172,1;172;170	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2320	porB1b	1041	1041	96.47	porB1b.l15.c4.ctg.1	1588	145.4	1	SNP	p	G120K	1	.	.	358	360	AAG	689	691	CGG	190;184;186	C;G,A;G	181;171,1;176	porB1b.WHO_M_02204c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2320	porB1b	1041	1041	96.47	porB1b.l15.c4.ctg.1	1588	145.4	1	SNP	p	A121D	1	.	.	361	363	GAC	692	695	CGC	186;187;191	C,G;G;C	174,1;176;181	porB1b.WHO_M_02204c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2320	porB1b	1041	1041	96.47	porB1b.l15.c4.ctg.1	1588	145.4	1	SNP	p	D121N	0	.	.	361	363	GAC	692	695	CGC	186;187;191	C,G;G;C	174,1;176;181	porB1b.WHO_M_02204c:1:1:D121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_F_02153c	rpoB.WHO_F_02153c	1	1	27	8686	rpoB	4179	4179	100.0	rpoB.l15.c4.ctg.1	4885	177.1	1	SNP	p	H553N	0	.	.	1657	1659	CAT	2043	2045	CAT	198;200;200	C,A;A;T	186,1;187;184	rpoB.WHO_F_02153c:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	970	rpsJ	312	312	100.0	rpsJ.l15.c4.ctg.1	1038	93.1	1	SNP	p	V57M	1	.	.	169	171	ATG	504	506	ATG	203;202;204	A;T;G,T	198;198;200,1	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
